Vimarsana
Biggest News Aggregation in the World

Page 24 - Immunic Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Inc Today - Breaking & Trending Today

Immunic, Inc. (NASDAQ:IMUX) Q4 2022 Earnings Call Transcript - Vimarsana News

Immunic, Inc. (NASDAQ:IMUX) Q4 2022 Earnings Call Transcript

Jessica Breu: Good morning and welcome to Immunic's Fourth Quarter and Year End 2022 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic.

Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update - Vimarsana News

Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Immunic, Inc. (NASDAQ: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

EQS-News: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 - Vimarsana News

EQS-News: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

Issuer: Immunic, Inc. / Key word(s): Conference/Study Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 22.02.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immun...

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 - Vimarsana News

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

EQS-News: Immunic, Inc.: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 - Vimarsana News

EQS-News: Immunic, Inc.: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

Issuer: Immunic, Inc. / Key word(s): Conference/Study Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023